Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...
Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback